PARN Pengajuan SEC - Parnell Pharmaceuticals Holdings Ltd.- Laporan Tahunan, Pernyataan Kuasa, Prospektus

Mga Batayang Estadistika

CIK

1603429

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Parnell Pharmaceuticals Holdings Ltd.

SEC Filings (Chronological Order)

Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.

August 3, 2017	6-K/A	Parnell Pharmaceuticals Holdings 6-K/A (Current Report of Foreign Issuer) SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 F O R M 6-K/A REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2017 Commission File Number 333-196065 PARNELL PHARMACEUTICALS HOLDINGS LTD. (Name of Registrant) Unit 4, Century Estate 476 Gardeners Road Alexandria 2015 NSW Australia (Address of Principal Exe
August 3, 2017	EX-99	Credit Agreement, dated as of November 22, 2016, by and among Parnell, Inc., as Borrower, Parnell Pharmaceuticals Holdings Ltd and certain of its subsidiaries, as Guarantors, the Lenders party thereto, as Lenders, and SWK Funding LLC, as Agent. Exhibit 10.1 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION CREDIT AGREEMENT dated as of November , 2016 among PARNELL, INC. as Borrower, PARNELL PHARMACEUTICALS HOLDINGS LTD AND CERTAIN OF ITS SUBSIDIARIES as G
March 31, 2017	20-F	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) 20-F 1 f20f033017.htm FORM 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ Registration statement pursuant to section 12(b) or (g) of the Securities Exchange Act of 1934 or x Annual report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2016 or ☐ Transition report pursuant to section 1
March 31, 2017	EX-13.2	CERTIFICATION OF BRAD MCCARTHY, CHIEF FINANCIAL OFFICER OF PARNELL PHARMACEUTICALS HOLDINGS LTD PURSUANT TO SECTION 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Exhibit 13.2 CERTIFICATION OF BRAD MCCARTHY, CHIEF FINANCIAL OFFICER OF PARNELL PHARMACEUTICALS HOLDINGS LTD PURSUANT TO SECTION 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Parnell Pharmaceuticals Holdings Ltd (the "Company") on Form 20-F for the year ending December 31, 2016, as filed with the Securities and
March 31, 2017	EX-12.1	CERTIFICATION Exhibit 12.1 CERTIFICATION I, Robert Joseph, certify that: 1. I have reviewed this Annual Report on Form 20-F of Parnell Pharmaceuticals Holdings Ltd; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleadin
March 31, 2017	EX-12.2	CERTIFICATION Exhibit 12.2 CERTIFICATION I, Brad McCarthy, certify that: 1. I have reviewed this Annual Report on Form 20-F of Parnell Pharmaceuticals Holdings Ltd; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleadin
March 31, 2017	EX-13.1	CERTIFICATION OF ROBERT JOSEPH, CHIEF EXECUTIVE OFFICER OF PARNELL PHARMACEUTICALS HOLDINGS LTD PURSUANT TO SECTION 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Exhibit 13.1 CERTIFICATION OF ROBERT JOSEPH, CHIEF EXECUTIVE OFFICER OF PARNELL PHARMACEUTICALS HOLDINGS LTD PURSUANT TO SECTION 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Parnell Pharmaceuticals Holdings Ltd (the “Company”) on Form 20-F for the year ending December 31, 2016, as filed with the Securities and
March 21, 2017	6-K	Parnell Pharmaceuticals Holdings FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2017 Commission File Number: 333-196065 Parnell Pharmaceuticals Holdings Ltd (Translation of registrant's name into English) Unit 4, Century Estate 476 Gardeners Road Alexandria 2015 NSW
March 21, 2017	EX-99	Parnell Pharmaceuticals Holdings Ltd Announces Financial Results for the Year Ended December 31, 2016 EXHIBIT 99.1 Parnell Pharmaceuticals Holdings Ltd Announces Financial Results for the Year Ended December 31, 2016 OVERLAND PARK, Kan., March 21, 2017 (GLOBE NEWSWIRE) - Parnell Pharmaceuticals Holdings Ltd (OTC:PARNF), a fully integrated, commercial-stage pharmaceutical company focused on developing, manufacturing and marketing innovative animal health solutions, today announced financial results
January 3, 2017	15-12B	Parnell Pharmaceuticals Holdings 2B form15.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 333-196065 Parnell Pharmaceuticals Holdings Ltd (Exact name of r
December 21, 2016	POS AM	Parnell Pharmaceuticals Holdings AM posam1210778.htm As filed with the Securities and Exchange Commission on December 21, 2016 Registration No. 333-210778 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO Form F- 1 Registration Statement No. 333-210778 UNDER THE SECURITIES ACT OF 1933 PARNELL PHARMACEUTICALS HOLDINGS LTD (Exact name of Registrant as specified in its charter) No
December 21, 2016	POS AM	Parnell Pharmaceuticals Holdings PE3 POS AM 1 pe3tof-1.htm PE3 As filed with the Securities and Exchange Commission on December 21, 2016 Registration No. 333-209096 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 3 TO Form F-1 Registration Statement No. 333-209096 UNDER THE SECURITIES ACT OF 1933 PARNELL PHARMACEUTICALS HOLDINGS LTD (Exact name of Registrant as specified in its cha
December 21, 2016	S-8 POS	Parnell Pharmaceuticals Holdings POS As filed with the Securities and Exchange Commission on December 21, 2016 Registration No.
December 21, 2016	S-8 POS	Parnell Pharmaceuticals Holdings POS S-8 POS 1 posams8.htm As filed with the Securities and Exchange Commission on December 21, 2016 Registration No. 333-209491 Registration No. 333-197331 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT FILE NO. 333-209491 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT FILE NO. 333-197331 PARN
December 21, 2016	25	Parnell Pharmaceuticals Holdings form25.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 25 NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 333-196065 Parnell Pharmaceuticals Holdings Ltd, Nasdaq Global Market (Exact name of Issuer as specified in its charter, and name of Exchange where security is listed a
December 19, 2016	EX-99.1	Parnell Pharmaceuticals Holdings Ltd Files Form 25, Voluntarily Delisting Its Shares From NASDAQ EX-99.1 2 exh991.htm PRESS RELEASE EXHIBIT 99.1 Parnell Pharmaceuticals Holdings Ltd Files Form 25, Voluntarily Delisting Its Shares From NASDAQ OVERLAND PARK, Kan., Dec. 19, 2016 (GLOBE NEWSWIRE) - Parnell Pharmaceuticals Holdings Ltd (NASDAQ:PARN), a fully integrated, commercial-stage pharmaceutical company focused on developing, manufacturing and marketing innovative animal health solutions (“P
December 19, 2016	6-K	Parnell Pharmaceuticals Holdings FORM 6-K (Current Report of Foreign Issuer) EdgarFiling UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2016 Commission File Number: 333-196065 Parnell Pharmaceuticals Holdings Ltd (Translation of registrant's name into English) Unit 4, Century Estate 476 Gardeners Road Alexa
December 9, 2016	6-K	Parnell Pharmaceuticals Holdings FORM 6-K (Current Report of Foreign Issuer) EdgarFiling UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2016 Commission File Number: 333-196065 Parnell Pharmaceuticals Holdings Ltd (Translation of registrant's name into English) Unit 4, Century Estate 476 Gardeners Road Alexa
December 9, 2016	EX-99.1	Parnell Pharmaceuticals Holdings Ltd Announces Intention To Move From the NASDAQ OMX Global Market and Expects To Move To the OTC Pink® Open Market EdgarFiling EXHIBIT 99.1 Parnell Pharmaceuticals Holdings Ltd Announces Intention To Move From the NASDAQ OMX Global Market and Expects To Move To the OTC Pink? Open Market OVERLAND PARK, Kan., Dec. 09, 2016 (GLOBE NEWSWIRE) - Parnell Pharmaceuticals Holdings Ltd (NASDAQ:PARN), a fully integrated, commercial-stage pharmaceutical company focused on developing, manufacturing and marketing innovative
December 1, 2016	424B3	2,060,000 Shares Parnell Pharmaceuticals Holdings Ltd Ordinary Shares 424B3 1 f424b3120116.htm 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-209096 PROSPECTUS SUPPLEMENT NO. 3 To Prospectus dated February 17, 2016 as amended by Post-Effective Amendment dated March 18, 2016 2,060,000 Shares Parnell Pharmaceuticals Holdings Ltd Ordinary Shares This Prospectus Supplement No. 3 (this “Supplement”) amends and supplements our Prospectus dated February 17, 20
November 30, 2016	6-K	Parnell Pharmaceuticals Holdings FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2015 Commission File Number: 333-196065 PARNELL PHARMACEUTICALS HOLDINGS LTD Unit 4, Century Estate 476 Gardeners Road Alexandria 2015 NSW Australia (Address of principal executive offices) I
November 30, 2016	EX-99.1	Parnell Pharmaceuticals Holdings Ltd Announces $20 Million Secured Term Loan Facility EX-99.1 3 exh991.htm EXHIBIT 99.1 EXHIBIT 99.1 Parnell Pharmaceuticals Holdings Ltd Announces $20 Million Secured Term Loan Facility OVERLAND PARK, Kan., Nov. 22, 2016 (GLOBE NEWSWIRE) - Parnell Pharmaceuticals Holdings Ltd (NASDAQ:PARN), a fully integrated pharmaceutical company focused on developing, manufacturing and commercializing innovative animal health solutions, today announced that it ha
November 30, 2016	EX-10.1	____________________________________________________ CREDIT AGREEMENT dated as of November __, 2016 PARNELL, INC. as Borrower, PARNELL PHARMACEUTICALS HOLDINGS LTD AND CERTAIN OF ITS SUBSIDIARIES as Guarantors, THE LENDERS PARTY HERETO, as Lenders, S EX-10.1 2 exh101.htm EXHIBIT 10.1 EXHIBIT 10.1 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION CREDIT AGREEMENT dated as of November , 2016 among PARNELL, INC. as Borrower, PARNELL PHARMACEUTICALS HOLDINGS LTD AN
November 2, 2016	6-K	Parnell Pharmaceuticals Holdings FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2016 Commission File Number: 333-196065 Parnell Pharmaceuticals Holdings Ltd (Translation of registrant's name into English) Unit 4, Century Estate 476 Gardeners Road Alexandria 2015 N
November 2, 2016	EX-99.1	Parnell Pharmaceuticals Holdings Ltd Announces Financial Results for the Nine-Month Period Ended September 30, 2016 EdgarFiling EXHIBIT 99.1 Parnell Pharmaceuticals Holdings Ltd Announces Financial Results for the Nine-Month Period Ended September 30, 2016 OVERLAND PARK, Kansas, Nov. 02, 2016 (GLOBE NEWSWIRE) - Parnell Pharmaceuticals Holdings Ltd (NASDAQ:PARN), a fully integrated, commercial-stage pharmaceutical company focused on developing, manufacturing and marketing innovative animal health solutions, toda
August 4, 2016	424B3	2,060,000 Shares Parnell Pharmaceuticals Holdings Ltd Ordinary Shares Filed Pursuant to Rule 424(b)(3) Registration No. 333-209096 PROSPECTUS SUPPLEMENT NO. 3 To Prospectus dated February 17, 2016 as amended by Post-Effective Amendment dated March 18, 2016 2,060,000 Shares Parnell Pharmaceuticals Holdings Ltd Ordinary Shares This Prospectus Supplement No. 3 (this ?Supplement?) amends and supplements our Prospectus dated February 17, 2016 (the ?Prospectus?) as amende
August 4, 2016	6-K	Parnell Pharmaceuticals Holdings FORM 6-K (Current Report of Foreign Issuer) EdgarFiling UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2016 Commission File Number: 333-196065 Parnell Pharmaceuticals Holdings Ltd (Translation of registrant's name into English) Unit 4, Century Estate 476 Gardeners Road Alexand
August 4, 2016	EX-99.1	Parnell Pharmaceuticals Holdings Ltd Announces Financial Results for the Six-Month Period Ended June 30, 2016 EX-99.1 2 exh991.htm PRESS RELEASE EXHIBIT 99.1 Parnell Pharmaceuticals Holdings Ltd Announces Financial Results for the Six-Month Period Ended June 30, 2016 OVERLAND PARK, Kan., Aug. 04, 2016 (GLOBE NEWSWIRE) - Parnell Pharmaceuticals Holdings Ltd (NASDAQ:PARN), a fully integrated, commercial-stage pharmaceutical company focused on developing, manufacturing and marketing innovative animal health
May 31, 2016	6-K	Parnell Pharmaceuticals Holdings FORM 6-K (Current Report of Foreign Issuer) EdgarFiling UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 May 31, 2016 Commission File Number: 333-196065 Parnell Pharmaceuticals Holdings Ltd (Translation of registrant's name into English) Unit 4, Century Estate 476 Gardeners Road Alexandria 2015 NSW Aus
May 31, 2016	EX-99.1	Parnell Pharmaceuticals Holdings Ltd Announces Contract Manufacturing Agreement with Merial EdgarFiling EXHIBIT 99.1 Parnell Pharmaceuticals Holdings Ltd Announces Contract Manufacturing Agreement with Merial OVERLAND PARK, Kan., May 31, 2016 (GLOBE NEWSWIRE) - Parnell Pharmaceuticals Holdings Ltd (NASDAQ:PARN), a fully integrated, commercial-stage pharmaceutical company focused on developing, manufacturing and marketing innovative animal health solutions, today announced the commencemen
May 31, 2016	424B3	2,060,000 Shares Parnell Pharmaceuticals Holdings Ltd Ordinary Shares Filed Pursuant to Rule 424(b)(3) Registration No. 333-209096 PROSPECTUS SUPPLEMENT NO. 3 To Prospectus dated February 17, 2016 as amended by Post-Effective Amendment dated March 18, 2016 2,060,000 Shares Parnell Pharmaceuticals Holdings Ltd Ordinary Shares This Prospectus Supplement No. 3 (this ?Supplement?) amends and supplements our Prospectus dated February 17, 2016 (the ?Prospectus?) as amende
May 16, 2016	6-K	Parnell Pharmaceuticals Holdings FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2016 Commission File Number: 333-196065 PARNELL PHARMACEUTICALS HOLDINGS LTD Unit 4, Century Estate 476 Gardeners Road Alexandria 2015 NSW Australia (Address of principal executive offices) In
May 13, 2016	424B1	2,550,000 Ordinary Shares Parnell Pharmaceuticals Holdings Ltd Filed Pursuant to Rule 424(b)(1) Registration No. 333-210778 PROSPECTUS 2,550,000 Ordinary Shares Parnell Pharmaceuticals Holdings Ltd We are offering 2,550,000 ordinary shares in this offering. Our ordinary shares are currently quoted on The NASDAQ Global Market under the symbol ?PARN?. On May 11, 2016, the last reported sale price of our ordinary shares on The NASDAQ Global Market was $1.95. We
May 10, 2016	CORRESP	Parnell Pharmaceuticals Holdings ESP LADENBURG THALMANN & CO. INC. 570 Lexington Avenue, 11th Floor New York, New York 10022 May 10, 2016 VIA EDGAR Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Attention: Ms. Suzanne Hayes Re: Parnell Pharmaceuticals Holdings Ltd ? Request for Acceleration Registration Statement on Form F-1, as amended File No. 333-210778 Dear Ms. Haye
May 10, 2016	CORRESP	Parnell Pharmaceuticals Holdings ESP Parnell Pharmaceuticals Holdings Ltd c/o Parnell, Inc. 7015 College Boulevard, Level 6 Overland Park, KS 66211 May 10, 2016 Via Edgar Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Mail Stop 4720 Washington, D.C. 20549 Attention: Ms. Suzanne Hayes Re: Parnell Pharmaceuticals Holdings Ltd Registration Statement on Form F-1 Filed April 15, 2016, as amended File
May 3, 2016	CORRESP	Parnell Pharmaceuticals Holdings ESP LADENBURG THALMANN & CO. INC. 570 Lexington Avenue, 11th Floor New York, New York 10022 May 3, 2016 VIA EDGAR Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Attention: Ms. Suzanne Hayes Re: Parnell Pharmaceuticals Holdings Ltd ? Request for Acceleration Registration Statement on Form F-1, as amended File No. 333-210778 Dear Ms. Hayes
May 3, 2016	CORRESP	Parnell Pharmaceuticals Holdings ESP Parnell Pharmaceuticals Holdings Ltd c/o Parnell, Inc. 7015 College Boulevard, Level 6 Overland Park, KS 66211 May 3, 2016 Via Edgar Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Mail Stop 4720 Washington, D.C. 20549 Attention: Ms. Suzanne Hayes Re: Parnell Pharmaceuticals Holdings Ltd Registration Statement on Form F-1 Filed April 15, 2016, as amended File
April 29, 2016	F-1/A	Parnell Pharmaceuticals Holdings FORM F-1/A Registration No. 333-210778 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 PARNELL PHARMACEUTICALS HOLDINGS LTD (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant?s name into English) Australia 2834 Not Applicable (State or other jurisdiction of
April 29, 2016	EX-1.1	Parnell Pharmaceuticals Holdings Ltd [●] Ordinary Shares UNDERWRITING AGREEMENT EX-1.1 2 exh11.htm EXHIBIT 1.1 Exhibit 1.1 Parnell Pharmaceuticals Holdings Ltd [●] Ordinary Shares UNDERWRITING AGREEMENT May [●], 2016 LADENBURG THALMANN & CO. INC. As Representative of the several Underwriters Ladenburg Thalmann & Co. Inc. 570 Lexington Avenue, 11th Floor New York, New York 10022 Ladies and Gentlemen: Introductory. Parnell Pharmaceuticals Holdings Ltd, a public company limited
April 29, 2016	CORRESP	Parnell Pharmaceuticals Holdings ESP CORRESP 1 filename1.htm Peter Mirakian III Direct Dial: (816) 292-8158 [email protected] 5021953-16 April 29, 2016 Via Edgar Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Mail Stop 4720 Washington, D.C. 20549 Attention: Ms. Suzanne Hayes Re: Parnell Pharmaceuticals Holdings Ltd Registration Statement on Form F-1 Filed April 15, 2016 File No. 333-2107
April 22, 2016	424B3	2,060,000 Shares Parnell Pharmaceuticals Holdings Ltd Ordinary Shares Filed Pursuant to Rule 424(b)(3) Registration No. 333-209096 PROSPECTUS SUPPLEMENT NO. 2 To Prospectus dated February 17, 2016 as amended by Post-Effective Amendment dated March 18, 2016 2,060,000 Shares Parnell Pharmaceuticals Holdings Ltd Ordinary Shares This Prospectus Supplement No. 2 (this ?Supplement?) amends and supplements our Prospectus dated February 17, 2016 (the ?Prospectus?) as amende
April 22, 2016	EX-99.1	Parnell Pharmaceuticals Holdings Ltd Announces First Quarter Business Update EdgarFiling EXHIBIT 99.1 Parnell Pharmaceuticals Holdings Ltd Announces First Quarter Business Update Parnell continues to grow rapidly with revenue increasing 43% for the three months ended March 31, 2016 OVERLAND PARK, Kan., April 22, 2016 (GLOBE NEWSWIRE) - Parnell Pharmaceuticals Holdings Ltd (NASDAQ:PARN), a fully integrated, commercial-stage pharmaceutical company focused on developing, manu
April 22, 2016	6-K	Parnell Pharmaceuticals Holdings FORM 6-K (Current Report of Foreign Issuer) 6-K 1 f6k042216.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2016 Commission File Number: 333-196065 Parnell Pharmaceuticals Holdings Ltd (Translation of registrant's name into English) Unit 4, Century Estate 476 Garden
April 15, 2016	F-1	Parnell Pharmaceuticals Holdings FORM F-1 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 PARNELL PHARMACEUTICALS HOLDINGS LTD (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant?s name into English) Australia 2834 Not Applicable (State or other jurisdiction of (Primary Standard Indust
April 7, 2016	6-K	Parnell Pharmaceuticals Holdings FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2016 Commission File Number: 333-196065 PARNELL PHARMACEUTICALS HOLDINGS LTD Unit 4, Century Estate 476 Gardeners Road Alexandria 2015 NSW Australia (Address of principal executive offices)
April 7, 2016	EX-99.1	NOTICE OF ANNUAL GENERAL MEETING AND EXPLANATORY MEMORANDUM EX-99.1 2 exh991.htm EXHIBIT 99.1 Exhibit 99.1 NOTICE OF ANNUAL GENERAL MEETING AND EXPLANATORY MEMORANDUM Notice is given that the Annual General Meeting of shareholders of Parnell Pharmaceuticals Holdings Ltd (Company) will be held on: Thursday 5 May 2016 at 4:00 p.m. (Central Standard Time) and Friday 6 May 2016 at 7:00 a.m. (Australian Eastern Standard Time). Meeting to be held by teleconferen
March 18, 2016	POS AM	Parnell Pharmaceuticals Holdings POST-EFFECTIVE AMENDMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 2 TO Form F-1 Registration Statement No. 333-209096 UNDER THE SECURITIES ACT OF 1933 PARNELL PHARMACEUTICALS HOLDINGS LTD (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant?s name into English) Australia 2834 Not Applicable (State or other jurisdiction
March 18, 2016	CORRESP	Parnell Pharmaceuticals Holdings ESP Parnell Pharmaceuticals Holdings Ltd c/o Parnell, Inc. 7015 College Boulevard, Level 6 Overland Park, KS 66211 March 18, 2016 Via Edgar Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Mail Stop 4720 Washington, D.C. 20549 Attention: Ms. Suzanne Hayes Re: Parnell Pharmaceuticals Holdings Ltd Post-Effective Amendment No. 1 to Form F-1 Filed March 8, 2016 File No
March 8, 2016	POS AM	Parnell Pharmaceuticals Holdings POST-EFFECTIVE AMENDMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO Form F-1 Registration Statement No. 333-209096 UNDER THE SECURITIES ACT OF 1933 PARNELL PHARMACEUTICALS HOLDINGS LTD (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant?s name into English) Australia 2834 Not Applicable (State or other jurisdiction
March 4, 2016	424B3	2,060,000 Shares Parnell Pharmaceuticals Holdings Ltd Ordinary Shares Filed Pursuant to Rule 424(b)(3) Registration No. 333-209096 PROSPECTUS SUPPLEMENT NO. 1 To Prospectus dated February 17, 2016 2,060,000 Shares Parnell Pharmaceuticals Holdings Ltd Ordinary Shares This Prospectus Supplement No. 1 (this ?Supplement?) amends and supplements our Prospectus dated February 17, 2016 (the ?Prospectus?), which forms a part of our Registration Statement (our ?Registration
March 4, 2016	20-F	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F 20-F 1 f20f030216.htm FORM 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ Registration statement pursuant to section 12(b) or (g) of the Securities Exchange Act of 1934 or x Annual report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2015 or ☐ Transition report pursuant to section 1
March 4, 2016	EX-14.1	Consent of Independent Registered Public Accounting Firm Exhibit 14.1 Consent of Independent Registered Public Accounting Firm We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (No. 333-197331 and No. 333-209491) of Parnell Pharmaceuticals Holdings Ltd of our report dated 4 March 2016 relating to the consolidated financial statements of Parnell Pharmaceuticals Holdings Ltd, which appears in this Form 20-F. /s
March 4, 2016	EX-12.2	CERTIFICATION Exhibit 12.2 CERTIFICATION I, Brad McCarthy, certify that: 1. I have reviewed this Annual Report on Form 20-F of Parnell Pharmaceuticals Holdings Ltd; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleadin
March 4, 2016	EX-13.2	CERTIFICATION OF BRAD MCCARTHY, CHIEF FINANCIAL OFFICER OF PARNELL PHARMACEUTICALS HOLDINGS LTD PURSUANT TO SECTION 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Exhibit 13.2 CERTIFICATION OF BRAD MCCARTHY, CHIEF FINANCIAL OFFICER OF PARNELL PHARMACEUTICALS HOLDINGS LTD PURSUANT TO SECTION 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Parnell Pharmaceuticals Holdings Ltd (the “Company”) on Form 20-F for the year ending December 31, 2015, as filed with the Securities and
March 4, 2016	EX-13.1	CERTIFICATION OF ROBERT JOSEPH, CHIEF EXECUTIVE OFFICER OF PARNELL PHARMACEUTICALS HOLDINGS LTD PURSUANT TO SECTION 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Exhibit 13.1 CERTIFICATION OF ROBERT JOSEPH, CHIEF EXECUTIVE OFFICER OF PARNELL PHARMACEUTICALS HOLDINGS LTD PURSUANT TO SECTION 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Parnell Pharmaceuticals Holdings Ltd (the “Company”) on Form 20-F for the year ending December 31, 2015, as filed with the Securities and
March 4, 2016	EX-12.1	CERTIFICATION Exhibit 12.1 CERTIFICATION I, Robert Joseph, certify that: 1. I have reviewed this Annual Report on Form 20-F of Parnell Pharmaceuticals Holdings Ltd; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleadin
March 3, 2016	6-K	Parnell Pharmaceuticals Holdings FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2016 Commission File Number: 333-196065 PARNELL PHARMACEUTICALS HOLDINGS LTD Unit 4, Century Estate 476 Gardeners Road Alexandria 2015 NSW Australia (Address of principal executive offices)
March 3, 2016	EX-10	SECURITIES PURCHASE AGREEMENT EX-10 3 exh10.htm EXHIBIT 10 Exhibit 10 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (the “Agreement”) is made as of the 23rd day of February, 2016 by and between PARNELL PHARMACEUTICALS HOLDINGS LTD, a public company limited by shares incorporated under the laws of Australia (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (the “Invest
March 3, 2016	EX-4	PARNELL PHARMACEUTICALS HOLDINGS LTD Warrant To Purchase Ordinary Shares Exhibit 4 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS.
February 24, 2016	6-K	Parnell Pharmaceuticals Holdings FORM 6-K (Current Report of Foreign Issuer) 6-K 1 f6k022416.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2016 Commission File Number: 333-196065 Parnell Pharmaceuticals Holdings Ltd (Translation of registrant's name into English) Unit 4, Century Estate 476 Gar
February 24, 2016	EX-99.1	Parnell Pharmaceuticals Holdings Ltd Announces Financial Results for the Year Ended December 31, 2015 Strong Growth in the U.S. Market Drives Revenue 58% Higher to $13.2 Million for the Year Ended December 31, 2015 EX-99.1 2 exh991.htm PRESS RELEASE EXHIBIT 99.1 Parnell Pharmaceuticals Holdings Ltd Announces Financial Results for the Year Ended December 31, 2015 Strong Growth in the U.S. Market Drives Revenue 58% Higher to $13.2 Million for the Year Ended December 31, 2015 OVERLAND PARK, Kan., Feb. 24, 2016 (GLOBE NEWSWIRE) - Parnell Pharmaceuticals Holdings Ltd (NASDAQ:PARN), a fully integrated, commercial
February 17, 2016	424B3	2,060,000 Shares Parnell Pharmaceuticals Holdings Ltd Ordinary Shares 424B3 1 f424b3021716.htm FORM 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-209096 PROSPECTUS 2,060,000 Shares Parnell Pharmaceuticals Holdings Ltd Ordinary Shares This prospectus relates to the offer and sale of up to 2,060,000 ordinary shares of Parnell Pharmaceuticals Holdings Ltd, an Australian public company limited by shares, by Lincoln Park Capital Fund, LLC, or Lincoln Park o
February 16, 2016	F-1/A	Parnell Pharmaceuticals Holdings FORM F-1/A Registration No. 333-209096 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 PARNELL PHARMACEUTICALS HOLDINGS LTD (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant?s name into English) Australia 2834 Not Applicable (State or other jurisdiction of
February 12, 2016	SC 13G/A	PARN / Parnell Pharmaceuticals Holdings Ltd. / Bell Alan R. - SCHEDULE 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. 1)* UNDER THE SECURITIES EXCHANGE ACT OF 1934 Parnell Pharmaceuticals Holdings Ltd (Name of Issuer) Ordinary Shares (Title of Class of Securities) Q73622104 (CUSIP Number) December 31, 2015 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursua
February 12, 2016	S-8	Parnell Pharmaceuticals Holdings S-8 As filed with the Securities and Exchange Commission on February 11, 2016 Registration No.
February 12, 2016	F-1/A	Parnell Pharmaceuticals Holdings FORM F-1/A Registration No. 333-209096 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 PARNELL PHARMACEUTICALS HOLDINGS LTD (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant?s name into English) Australia 2834 Not Applicable (State or other jurisdiction of
February 12, 2016	SC 13G/A	PARN / Parnell Pharmaceuticals Holdings Ltd. / Joseph Robert T. - SCHEDULE 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. 1)* UNDER THE SECURITIES EXCHANGE ACT OF 1934 Parnell Pharmaceuticals Holdings Ltd (Name of Issuer) Ordinary Shares (Title of Class of Securities) Q73622104 (CUSIP Number) December 31, 2015 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursua
February 11, 2016	CORRESP	Parnell Pharmaceuticals Holdings ESP Parnell Pharmaceuticals Holdings Ltd c/o Parnell, Inc. 7015 College Boulevard, Level 6 Overland Park, KS 66211 February 11, 2016 Via Edgar Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Mail Stop 4720 Washington, D.C. 20549 Attention: Mr. Michael Gershon Re: Parnell Pharmaceuticals Holdings Ltd Registration Statement on Form F-1 Filed January 25, 2016, as Ame
January 25, 2016	F-1	Parnell Pharmaceuticals Holdings FORM F-1 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 PARNELL PHARMACEUTICALS HOLDINGS LTD (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant?s name into English) Australia 2834 Not Applicable (State or other jurisdiction of (Primary Standard Indust
January 19, 2016	EX-99.1	Parnell Pharmaceuticals Holdings Ltd Announces Agreement With Lincoln Park Captial Fund to Purchase Ordinary Shares EdgarFiling EXHIBIT 99.1 Parnell Pharmaceuticals Holdings Ltd Announces Agreement With Lincoln Park Captial Fund to Purchase Ordinary Shares OVERLAND PARK, Kansas, Jan. 19, 2016 (GLOBE NEWSWIRE) - Parnell Pharmaceuticals Holdings Ltd. ("Parnell" or "Company") (NASDAQ:PARN), a fully integrated pharmaceutical company focused on developing, manufacturing and commercializing innovative animal health s
January 19, 2016	EX-99.2	EX-99.2 EX-99.2 3 exh992.htm EXHIBIT 99.2 Exhibit 99.2
January 19, 2016	6-K	Parnell Pharmaceuticals Holdings FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2016 Commission File Number: 333-196065 PARNELL PHARMACEUTICALS HOLDINGS LTD Unit 4, Century Estate 476 Gardeners Road Alexandria 2015 NSW Australia (Address of principal executive offices
January 19, 2016	EX-99.3	EX-99.3 Exhibit 99.3
December 17, 2015	EX-99.1	Parnell Appoints Ellen B. Richstone and Dr. David K. Rosen to the Board of Directors Appointments Increase the Board to Six Members, Three of Whom Are Independent EdgarFiling EXHIBIT 99.1 Parnell Appoints Ellen B. Richstone and Dr. David K. Rosen to the Board of Directors Appointments Increase the Board to Six Members, Three of Whom Are Independent OVERLAND PARK, Kansas, Dec. 17, 2015 (GLOBE NEWSWIRE) - Parnell Pharmaceuticals Holdings Ltd (Nasdaq:PARN), a fully integrated pharmaceutical company focused on developing, manufacturing and commercializing innov
December 17, 2015	6-K	Parnell Pharmaceuticals Holdings FORM 6-K (Current Report of Foreign Issuer) EdgarFiling UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2015 Commission File Number: 333-196065 Parnell Pharmaceuticals Holdings Ltd (Translation of registrant's name into English) Unit 4, Century Estate 476 Gardeners Road Alexa
October 21, 2015	EX-99	Parnell Pharmaceuticals Holdings Ltd Announces Third Quarter Business Results EX-99 2 newsrelease.htm PRESS RELEASE EXHIBIT 99.1 Parnell Pharmaceuticals Holdings Ltd Announces Third Quarter Business Results Parnell Continues to Grow Rapidly With Revenue Increasing 55% for the Nine Months Ended September 30, 2015 OVERLAND PARK, Kansas, Oct. 21, 2015 (GLOBE NEWSWIRE) - Parnell Pharmaceuticals Holdings Ltd (NASDAQ:PARN), a fully integrated, commercial-stage pharmaceutical comp
October 21, 2015	6-K	Parnell Pharmaceuticals Holdings FORM 6-K FILING DOCUMENT (Current Report of Foreign Issuer) 6-K 1 document.htm FORM 6-K FILING DOCUMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2015. Commission File Number: 333-196065 Parnell Pharmaceuticals Holdings Ltd Unit 4, Century Estate 476 Gardeners Road Alexandria 2015 NSW A
October 9, 2015	EX-99	Parnell Pharmaceuticals Holdings Ltd Restructures Board EXHIBIT 99.1 Parnell Pharmaceuticals Holdings Ltd Restructures Board OVERLAND PARK, Kansas, Oct. 9, 2015 (GLOBE NEWSWIRE) - Parnell Pharmaceuticals Holdings Ltd (NASDAQ:PARN), a fully integrated pharmaceutical company focused on developing, manufacturing and commercializing innovative animal health solutions, today announced changes in the structure of its Board of Directors including the engageme
October 9, 2015	6-K	Parnell Pharmaceuticals Holdings FORM 6-K FILING DOCUMENT (Current Report of Foreign Issuer) Form 6-K Filing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2015. Commission File Number: 333-196065 Parnell Pharmaceuticals Holdings Ltd Unit 4, Century Estate 476 Gardeners Road Alexandria 2015 NSW Australia (Address of princip
August 12, 2015	EX-99.2	Parnell Appoints Peter A. Croden to Board of Directors Parnell Appoints Peter A. Croden to Board of Directors EXHIBIT 99.2 Parnell Appoints Peter A. Croden to Board of Directors Appointment increases Board to seven members, four of whom are independent OVERLAND PARK, Kansas, Aug. 10, 2015 (GLOBE NEWSWIRE) - Parnell Pharmaceuticals Holdings Ltd (Nasdaq:PARN), a fully integrated pharmaceutical company focused on developing, manufacturing and commerciali
August 12, 2015	EX-99.1	Parnell Pharmaceuticals Holdings Ltd Announces Financial Results for the Six-Month Period Ended June 30, 2015 Parnell Pharmaceuticals Holdings Ltd Announces Financial Results for the Six-Month Period Ended June 30, 2015 EXHIBIT 99.
August 12, 2015	6-K	Parnell Pharmaceuticals Holdings FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2015 Commission File Number: 333-196065 PARNELL PHARMACEUTICALS HOLDINGS LTD Unit 4, Century Estate 476 Gardeners Road Alexandria 2015 NSW Australia (Address of principal executive offices)
June 18, 2015	EX-99.2	Parnell Pharmaceuticals Holdings Ltd Investor Day Highlights EX-99.2 3 exh992.htm EXHIBIT 99.2 EXHIBIT 99.2 Parnell Pharmaceuticals Holdings Ltd Investor Day Highlights Company Presents Detailed Zydax Trial Results and Commercialization Plans, Guidance on Marketed Products and Pipeline Progress; Industry Experts Highlight Growth in Industry OVERLAND PARK, Kansas, June 18, 2015 (GLOBE NEWSWIRE) - Parnell Pharmaceuticals Holdings Ltd (Nasdaq:PARN), a fully in
June 18, 2015	6-K	Parnell Pharmaceuticals Holdings FORM 6-K (Current Report of Foreign Issuer) 6-K 1 f6k061815.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2015 Commission File Number: 333-196065 PARNELL PHARMACEUTICALS HOLDINGS LTD Unit 4, Century Estate 476 Gardeners Road Alexandria 2015 NSW Australia (Address of p
June 18, 2015	EX-99.1	Parnell Pharmaceuticals Holdings Ltd Announces Positive Top-Line Pivotal Trial Results for Zydax(R), Disease-Modifying Osteoarthritis Drug in Dogs EX-99.1 2 exh991.htm EXHIBIT 99.1 EXHIBIT 99.1 Parnell Pharmaceuticals Holdings Ltd Announces Positive Top-Line Pivotal Trial Results for Zydax(R), Disease-Modifying Osteoarthritis Drug in Dogs – Detailed Zydax Trial Results to be Presented Today at Company Investor Day – Meeting to be Webcast Beginning at 8:30 AM ET OVERLAND PARK, Kansas, June 18, 2015 (GLOBE NEWSWIRE) - Parnell Pharmaceuticals H
June 18, 2015	EX-10.1	EX-10.1 EX-10.1 5 exh101.htm EXHIBIT 10.1 EXHIBIT 10.1
June 18, 2015	EX-99.3	Parnell Pharmaceuticals Holdings Ltd Announces $11 Million Secured Term Loan Facility Parnell Pharmaceuticals Holdings Ltd Announces $11 Million Secured Term Loan Facility EXHIBIT 99.
May 7, 2015	EX-3.1	EX-3.1 exh31.htm Exhibit 3.1
May 7, 2015	6-K	Parnell Pharmaceuticals Holdings FORM 6-K (Current Report of Foreign Issuer) f6k050115.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2015 Commission File Number: 333-196065 PARNELL PHARMACEUTICALS HOLDINGS LTD Unit 4, Century Estate 476 Gardeners Road Alexandria 2015 NSW Australia (Address of principal executi
May 7, 2015	EX-10.2	Parnell Pharmaceuticals Holdings Ltd 2014 Omnibus Incentive Plan Award Agreement EX-10.2 4 exh102.htm EXHIBIT 10.2 Exhibit 10.2 Parnell Pharmaceuticals Holdings Ltd 2014 Omnibus Incentive Plan Award Agreement You have been selected to be a Participant in the Parnell Pharmaceuticals Holdings Ltd 2014 Omnibus Incentive Plan (the “Plan”), as specified below: Participant: Date of Award: Term: Options Awarded: Exercise Price: Equity Restricted Share Units Awarded: Bonus Restricted
May 7, 2015	EX-10.1	EX-10.1 EX-10.1 3 exh101.htm EXHIBIT 10.1 Exhibit 10.1
April 22, 2015	EX-99	Parnell Pharmaceuticals Holdings Ltd Announces First Quarter Business Results Parnell Pharmaceuticals Holdings Ltd Announces First Quarter Business Results EXHIBIT 99.
April 22, 2015	6-K	Parnell Pharmaceuticals Holdings FORM 6-K FILING DOCUMENT (Current Report of Foreign Issuer) Form 6-K Filing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2015. Commission File Number: 333-196065 Parnell Pharmaceuticals Holdings Ltd Unit 4, Century Estate 476 Gardeners Road Alexandria 2015 NSW Australia (Address of principal
March 24, 2015	6-K	Parnell Pharmaceuticals Holdings FORM 6-K (Current Report of Foreign Issuer) f6k032415.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2015 Commission File Number: 333-196065 PARNELL PHARMACEUTICALS HOLDINGS LTD Unit 4, Century Estate 476 Gardeners Road Alexandria 2015 NSW Australia (Address of principal execu
March 24, 2015	EX-99.1	24 March 2015 Exhibit 99.1 NOTICE OF ANNUAL GENERAL MEETING AND EXPLANATORY MEMORANDUM Notice is given that the Annual General Meeting of shareholders of Parnell Pharmaceuticals Holdings Ltd (Company) will be held on: Tuesday 21 April 2015 at 3:00 p.m. (Central Standard Time) and Wednesday 22 April 2015 at 6:00 a.m. (Australian Eastern Standard Time). Meeting to be held by teleconference (Dial-in details below)
March 24, 2015	EX-99.2	THE PROPOSED ALTERATIONS TO THE CONSTITUTION OF PARNELL PHARMACEUTICALS HOLDINGS LTD EX-99.2 3 exh992.htm EXHIBIT 99.2 Exhibit 99.2 THE PROPOSED ALTERATIONS TO THE CONSTITUTION OF PARNELL PHARMACEUTICALS HOLDINGS LTD The alterations which are proposed to be made to the Constitution are set out below. Rule 3.11 Issues to Directors and their Associates A Director or any person who for the purposes of Section 9 of the Act would be regarded as a person associated with that Director (“
March 24, 2015	EX-99.3	AMENDMENT NO. 1 TO THE PARNELL PHARMACEUTICALS HOLDINGS LTD 2014 OMNIBUS EQUITY INCENTIVE PLAN exh993.htm Exhibit 99.3 AMENDMENT NO. 1 TO THE PARNELL PHARMACEUTICALS HOLDINGS LTD 2014 OMNIBUS EQUITY INCENTIVE PLAN WHEREAS, Parnell Pharmaceuticals Holdings Ltd, an Australian company limited by shares (?Parnell?), previously established the Parnell Pharmaceuticals Holdings Ltd 2014 Omnibus Equity Incentive Plan, effective on 3 June, 2014 (the ?Plan?), in order to attract and retain management
March 2, 2015	SC 13G	PARN / Parnell Pharmaceuticals Holdings Ltd. / Bell Alan R. - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. )* UNDER THE SECURITIES EXCHANGE ACT OF 1934 Parnell Pharmaceuticals Holdings Ltd (Name of Issuer) Ordinary Shares (Title of Class of Securities) Q73622104 (CUSIP Number) December 31, 2014 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuan
February 27, 2015	EX-12.2	CERTIFICATION I, Brad McCarthy, certify that: 1. I have reviewed this transition report on Form 20-F of Parnell Pharmaceuticals Holdings Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to s Exhibit 12.2 CERTIFICATION I, Brad McCarthy, certify that: 1. I have reviewed this transition report on Form 20-F of Parnell Pharmaceuticals Holdings Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misl
February 27, 2015	EX-13.1	CERTIFICATION OF ROBERT JOSEPH, CHIEF EXECUTIVE OFFICER OF PARNELL PHARMACEUTICALS HOLDINGS LTD PURSUANT TO SECTION 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Exhibit 13.1 CERTIFICATION OF ROBERT JOSEPH, CHIEF EXECUTIVE OFFICER OF PARNELL PHARMACEUTICALS HOLDINGS LTD PURSUANT TO SECTION 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Transition Report of Parnell Pharmaceuticals Holdings Ltd. (the “Company”) on Form 20-F for the period ending December 31, 2014, as filed with the Securiti
February 27, 2015	EX-12.1	CERTIFICATION I, Robert Joseph, certify that: 1. I have reviewed this transition report on Form 20-F of Parnell Pharmaceuticals Holdings Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to s Exhibit 12.1 CERTIFICATION I, Robert Joseph, certify that: 1. I have reviewed this transition report on Form 20-F of Parnell Pharmaceuticals Holdings Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misl
February 27, 2015	20-F	PARN / Parnell Pharmaceuticals Holdings Ltd. 20-F - - FORM 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ¨ Registration statement pursuant to section 12(b) or (g) of the Securities Exchange Act of 1934 or ¨ Annual report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2014 or x Transition report pursuant to section 13 or 15(d) of the Securities Exc
February 27, 2015	EX-13.2	CERTIFICATION OF BRAD MCCARTHY, CHIEF FINANCIAL OFFICER OF PARNELL PHARMACEUTICALS HOLDINGS LTD PURSUANT TO SECTION 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Transition Report Exhibit 13.2 CERTIFICATION OF BRAD MCCARTHY, CHIEF FINANCIAL OFFICER OF PARNELL PHARMACEUTICALS HOLDINGS LTD PURSUANT TO SECTION 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Transition Report of Parnell Pharmaceuticals Holdings Ltd. (the “Company”) on Form 20-F for the period ending December 31, 2014, as filed with the Securiti
February 27, 2015	EX-14.1	Consent of Independent Registered Public Accounting Firm Exhibit 14.1 Consent of Independent Registered Public Accounting Firm We hereby consent to the incorporation by reference in the Registration Statement on Form S-8 (No. 333-197331) of Parnell Pharmaceuticals Holdings Ltd of our report dated 27 February 2015 relating to the consolidated financial statements of Parnell Pharmaceuticals Holdings Ltd, which appears in this Form 20-F. /s/ Pricewaterhous
February 25, 2015	6-K	PARN / Parnell Pharmaceuticals Holdings Ltd. 6-K - Current Report of Foreign Issuer - FORM 6-K FILING DOCUMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2015. Commission File Number: 333-196065 Parnell Pharmaceuticals Holdings Ltd Unit 4, Century Estate 476 Gardeners Road Alexandria 2015 NSW Australia (Address of principal executive of
February 25, 2015	EX-99	Parnell Pharmaceuticals Holdings Ltd Announces Financial Results for the Six-Month Period Ended December 31, 2014 EXHIBIT 99.1 Parnell Pharmaceuticals Holdings Ltd Announces Financial Results for the Six-Month Period Ended December 31, 2014 OVERLAND PARK, Kan., Feb. 25, 2015 (GLOBE NEWSWIRE) - Parnell Pharmaceuticals Holdings Ltd (Nasdaq:PARN), a fully integrated, commercial stage pharmaceutical company focused on developing, manufacturing and marketing innovative animal health solutions, today announced fina
February 20, 2015	SC 13G	PARN / Parnell Pharmaceuticals Holdings Ltd. / Joseph Robert T. - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. )* UNDER THE SECURITIES EXCHANGE ACT OF 1934 Parnell Pharmaceuticals Holdings Ltd (Name of Issuer) Ordinary Shares (Title of Class of Securities) Q73622104 (CUSIP Number) December 31, 2014 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuan
December 10, 2014	EX-99	Parnell Announces Key Senior Management and Director Appointments EXHIBIT 99.1 Parnell Announces Key Senior Management and Director Appointments OVERLAND PARK, Kan., Dec. 9, 2014 (GLOBE NEWSWIRE) - Parnell Pharmaceuticals Holdings Ltd., a fully integrated pharmaceutical company focused on developing, manufacturing and commercializing innovative animal health solutions, today announced the appointments of Edward Robb, DVM as Chief Scientific Officer, Andy Ferrign
December 10, 2014	6-K	PARN / Parnell Pharmaceuticals Holdings Ltd. 6-K - Current Report of Foreign Issuer - FORM 6-K FILING DOCUMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2014. Commission File Number: 333-196065 Parnell Pharmaceuticals Holdings Ltd Unit 4, Century Estate 476 Gardeners Road Alexandria 2015 NSW Australia (Address of principal executive of
December 9, 2014	EX-99	Parnell Pharmaceuticals Holdings Ltd Announces Change in Fiscal Year-End EXHIBIT 99.1 Parnell Pharmaceuticals Holdings Ltd Announces Change in Fiscal Year-End OVERLAND PARK, Kan., Dec. 9, 2014 (GLOBE NEWSWIRE) - Parnell Pharmaceuticals Holdings Ltd (Nasdaq:PARN), a fully integrated pharmaceutical company focused on developing, manufacturing and commercializing innovative animal health solutions, reported today that the Company's Board of Directors approved a fiscal yea
December 9, 2014	6-K	PARN / Parnell Pharmaceuticals Holdings Ltd. 6-K - Current Report of Foreign Issuer - FORM 6-K FILING DOCUMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2014. Commission File Number: 333-196065 Parnell Pharmaceuticals Holdings Ltd Unit 4, Century Estate 476 Gardeners Road Alexandria 2015 NSW Australia (Address of principal executive of
November 4, 2014	EX-99.1	EX-99.1 Exhibit 99.1
November 4, 2014	6-K	PARN / Parnell Pharmaceuticals Holdings Ltd. 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2014 Commission File Number: 333-196065 PARNELL PHARMACEUTICALS HOLDINGS LTD Unit 4, Century Estate 476 Gardeners Road Alexandria 2015 NSW Australia (Address of principal executive office
September 15, 2014	EX-14.1	Consent of Independent Registered Public Accounting Firm Exhibit 14.1 Consent of Independent Registered Public Accounting Firm We hereby consent to the incorporation by reference in the Registration Statement on Form S-8 (No. 333-197331) of Parnell Pharmaceuticals Holdings Ltd of our report dated 15 September 2014 relating to the consolidated financial statements of Parnell Pharmaceuticals Holdings Ltd, which appears in this Form 20-F. /s/ Pricewaterhou
September 15, 2014	EX-99	Parnell Pharmaceuticals Holdings Ltd Announces Fiscal Year 2014 Financial Results EXHIBIT 99.1 Parnell Pharmaceuticals Holdings Ltd Announces Fiscal Year 2014 Financial Results OVERLAND PARK, Kan., Sept. 15, 2014 (GLOBE NEWSWIRE) - Parnell Pharmaceuticals Holdings Ltd (Nasdaq:PARN), a fully integrated pharmaceutical company focused on developing, manufacturing and commercializing innovative animal health solutions, today announced year-end financial results. The company's fisca
September 15, 2014	20-F	PARN / Parnell Pharmaceuticals Holdings Ltd. 20-F - - FORM 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ¨ Registration statement pursuant to section 12(b) or (g) of the Securities Exchange Act of 1934 or x Annual report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended June 30, 2014 or ¨ Transition report pursuant to section 13 or 15(d) of the Securities Exchang
September 15, 2014	6-K	PARN / Parnell Pharmaceuticals Holdings Ltd. 6-K - Current Report of Foreign Issuer - FORM 6-K FILING DOCUMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of September 2014 Commission File Number: 333-196065 Parnell Pharmaceuticals Holdings Ltd Unit 4, Century Estate 476 Gardeners Road Alexandria 2015 NSW Australia (Address of principal executive of
September 15, 2014	EX-12.1	Robert Joseph Chief Executive Officer Exhibit 12.1 CERTIFICATION I, Robert Joseph, certify that: 1. I have reviewed this annual report on Form 20-F of Parnell Pharmaceuticals Holdings Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleadi
September 15, 2014	EX-4.17	OFFICE LEASE EX-4.17 2 exh417.htm EXHIBIT 4.17 Exhibit 4.17 OFFICE LEASE THIS LEASE (the "Lease") is made as of the 12th day of September, 2014 (the “Effective Date”), by and between RENAISSANCE PROPERTY OWNER, LLC, a Kansas limited liability company (“Landlord”) and PARNELL CORPORATE SERVICES U.S., INC., a Delaware corporation (“Tenant”). ARTICLE 1: BASIC LEASE PROVISIONS AND DEFINITIONS The descriptions and
September 15, 2014	EX-13.1	CERTIFICATION OF ROBERT JOSEPH, CHIEF EXECUTIVE OFFICER OF PARNELL PHARMACEUTICALS HOLDINGS LTD PURSUANT TO SECTION 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Exhibit 13.1 CERTIFICATION OF ROBERT JOSEPH, CHIEF EXECUTIVE OFFICER OF PARNELL PHARMACEUTICALS HOLDINGS LTD PURSUANT TO SECTION 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Parnell Pharmaceuticals Holdings Ltd. (the “Company”) on Form 20-F for the period ending June 30, 2014, as filed with the Securities and E
September 15, 2014	EX-12.2	Brad McCarthy Chief Financial Officer Exhibit 12.2 CERTIFICATION I, Brad McCarthy, certify that: 1. I have reviewed this annual report on Form 20-F of Parnell Pharmaceuticals Holdings Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleadi
September 15, 2014	EX-13.2	CERTIFICATION OF BRAD MCCARTHY, CHIEF FINANCIAL OFFICER OF PARNELL PHARMACEUTICALS HOLDINGS LTD PURSUANT TO SECTION 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Exhibit 13.2 CERTIFICATION OF BRAD MCCARTHY, CHIEF FINANCIAL OFFICER OF PARNELL PHARMACEUTICALS HOLDINGS LTD PURSUANT TO SECTION 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Parnell Pharmaceuticals Holdings Ltd. (the “Company”) on Form 20-F for the period ending June 30, 2014, as filed with the Securities and E
September 8, 2014	6-K	PARN / Parnell Pharmaceuticals Holdings Ltd. 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the Month of September 2014 Commission File Number: 333-196065 PARNELL PHARMACEUTICALS HOLDINGS LTD Unit 4, Century Estate 476 Gardeners Road Alexandria 2015 NSW Australia (Address of principal executive offic
September 8, 2014	EX-99.1	Parnell Appoints US-based Independent Directors Phyllis Gardner, M.D., and David L. Greenwood to its Board of Directors Australian-based Directors Andrew Want and Peter Molloy Step Down EX-99.1 2 v388709ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE For more information, contact: Robert Joseph, 816-654-3450 [email protected] Parnell Appoints US-based Independent Directors Phyllis Gardner, M.D., and David L. Greenwood to its Board of Directors Australian-based Directors Andrew Want and Peter Molloy Step Down Overland Park, Kansas, (September 8, 2014) — Parnell
September 3, 2014	EX-99.1	Parnell Announces Results from the Successful Efficacy Study for Zydax® Zydax effective in reducing osteoarthritis pain and interference in dogs in large-scale pilot efficacy study Exhibit 99.1 FOR IMMEDIATE RELEASE For more information, contact: Robert Joseph, 816-654-3450 [email protected] Parnell Announces Results from the Successful Efficacy Study for Zydax® Zydax effective in reducing osteoarthritis pain and interference in dogs in large-scale pilot efficacy study Overland Park, Kansas, (September 3, 2014) — Parnell Pharmaceuticals Holdings Ltd today announced t
September 3, 2014	6-K	PARN / Parnell Pharmaceuticals Holdings Ltd. 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the Month of September 2014 Commission File Number: 333-196065 PARNELL PHARMACEUTICALS HOLDINGS LTD Unit 4, Century Estate 476 Gardeners Road Alexandria 2015 NSW Australia (Address of principal executive offic
July 23, 2014	EX-99.1	Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration Company inks deal with CIMTECH Pty Ltd to develop new products for veterinary medicine FOR IMMEDIATE RELEASE For more information, contact: Erika Vikor, 913-312-0790 Erika.
July 23, 2014	6-K	PARN / Parnell Pharmaceuticals Holdings Ltd. 6-K - Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July 2014 Commission File Number: 333-196065 PARNELL PHARMACEUTICALS HOLDINGS LTD Unit 4, Century Estate 476 Gardeners Road Alexandria 2015 NSW Australia (Address of principal executive offices) I
July 10, 2014	S-8	PARN / Parnell Pharmaceuticals Holdings Ltd. S-8 - - S-8 As filed with the Securities and Exchange Commission on July 9, 2014 Registration No.
June 18, 2014	424B1	Parnell Pharmaceuticals Holdings Ltd JMP Securities Ladenburg Thalmann Geller Biopharm TABLE OF CONTENTS PROSPECTUS SUMMARY Overview THE OFFERING SUMMARY CONSOLIDATED FINANCIAL DATA RISK FACTORS SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS INDUS Filed Pursuant to Rule 424(b)(1) Registration No. 333-196065 PROSPECTUS 5,000,000 Shares Parnell Pharmaceuticals Holdings Ltd Ordinary Shares This is an initial public offering of ordinary shares of Parnell Pharmaceuticals Holdings Ltd, an Australian public company limited by shares. We are offering 5,000,000 ordinary shares. Prior to this offering, there has been no public market for our ordinary
June 18, 2014	F-1/A	- F-1/A As filed with the United States Securities and Exchange Commission on June 18, 2014 Registration No.
June 17, 2014	F-1/A	- FORM F-1/A As filed with the United States Securities and Exchange Commission on June 16, 2014 Registration No.
June 16, 2014	CORRESP	- Parnell Pharmaceuticals Holdings Ltd Unit 4, Century Estate 476 Gardeners Road Alexandria 2015 NSW Australia June 16, 2014 Via UPS and Email U.
June 13, 2014	F-1/A	- FORM F-1/A As filed with the United States Securities and Exchange Commission on June 13, 2014 Registration No.
June 13, 2014	8-A12B	- FORM 8-A12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Parnell Pharmaceuticals Holdings Ltd (Exact name of registrant as specified in its charter) Australia Not Applicable (State of incorporation or organization) (I.R.S. Employer Identification No.) Un
June 13, 2014	CORRESP	- June 13, 2014 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.
June 13, 2014	CORRESP	- Parnell Pharmaceuticals Holdings Ltd Unit 4, Century Estate 476 Gardeners Road Alexandria 2015 NSW Australia June 13, 2014 Via Edgar and Email U.
June 13, 2014	CORRESP	- June 13, 2014 Via EDGAR Submission Securities and Exchange Commission 100 F Street, N.
June 10, 2014	EX-10.13	Each entity described in Schedule 1 Partners for Growth III, L.P. Revenue Sharing Deed Exhibit 10.13 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION Each entity described in Schedule 1 and Partners for Growth III, L.P. Revenue Sharing Deed CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PO
June 10, 2014	EX-10.1	DISTRIBUTION AND SUPPLY AGREEMENT PARNELL NORTH AMERICA PTY LTD ABN 36 138 251 537 VÉTOQUINOL CANADA INC EX-10.1 3 v381039ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION DISTRIBUTION AND SUPPLY AGREEMENT PARNELL NORTH AMERICA PTY LTD ABN 36 138 251 537 and VÉTOQUINOL CANADA INC
June 10, 2014	EX-10.2	DISTRIBUTION AND SUPPLY AGREEMENT PARNELL EUROPE PTY LTD ABN A2 138 251 56A and ELANCO, a division of ELI LILLY and COMPANY Exhibit 10.2 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION DISTRIBUTION AND SUPPLY AGREEMENT PARNELL EUROPE PTY LTD ABN A2 138 251 56A and ELANCO, a division of ELI LILLY and COMPANY CONFIDENTIAL TREATMENT HAS
June 10, 2014	EX-10.12	Table of Contents Exhibit 10.12 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION LICENCE AGREEMENT CIMTECH PTY LIMITED and PARNELL TECHNOLOGIES PTY LTD CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUM
June 10, 2014	EX-10.5	SUPPLY AGREEMENT ON GONADORELIN ACETATE Exhibit 10.5 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION SUPPLY AGREEMENT ON GONADORELIN ACETATE This Agreement is made as of September 26, 2011 (the “Effective Date”) between Bachem AG, an entity organized
June 10, 2014	EX-1.1	Parnell Pharmaceuticals Holdings Ltd [●] Ordinary Shares UNDERWRITING AGREEMENT EX-1.1 2 v381039ex1-1.htm EXHIBIT 1.1 Exhibit 1.1 Parnell Pharmaceuticals Holdings Ltd [●] Ordinary Shares UNDERWRITING AGREEMENT June [●], 2014 JEFFERIES LLC PIPER JAFFRAY & CO As Representatives of the several Underwriters c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022 c/o PIPER JAFFRAY & CO 345 Park Avenue, 12th Floor New York, New York 10154 Ladies and Gentlemen: Introductory. P
June 10, 2014	EX-10.9	Supply Agreement for Pentosan Polysufate Active Pharmaceutical Ingredient Parnell Manufacturing Pty Ltd (ABN 46 138 251 582) IDT Australia Limited (ABN 66 066 522 970) Effective Date: 3 December 2013 EX-10.9 7 v381039ex10-9.htm EXHIBIT 10.9 Exhibit 10.9 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION Supply Agreement for Pentosan Polysufate Active Pharmaceutical Ingredient Between Parnell Manufacturing Pty L
June 10, 2014	EX-10.11	SUPPLY AGREEMENT Exhibit 10.11 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION SUPPLY AGREEMENT This Supply Agreement (this “Agreement”) entered into on the 1st day of January 2014, is made by and between Parnell Manufacturing P
June 10, 2014	F-1/A	- F-1/A As filed with the United States Securities and Exchange Commission on June 10, 2014 Registration No.
June 10, 2014	EX-10.3	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK *, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION EX-10.3 5 v381039ex10-3.htm EXHIBIT 10.3 Exhibit 10.3 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK *, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION Distribution and Supply Agreement Amendment 1 Parnell Europe Pty Limited AND Eli Lilly and Company CONFIDENTI
June 10, 2014	EX-10.10	CREDIT AGREEMENT dated as of January 23, 2014 PARNELL PHARMACEUTICALS HOLDINGS PTY LTD, and PARNELL, INC. as Borrowers, THE SUBSIDIARIES OF THE BORROWERS, as Guarantors, THE LENDERS PARTY HERETO, as Lenders, SWK FUNDING LLC, as Agent, Sole Lead Arran EX-10.10 8 v381039ex10-10.htm EXHIBIT 10.10 Exhibit 10.10 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CREDIT AGREEMENT dated as of January 23, 2014 among PARNELL PHARMACEUTICALS HOLDINGS PTY LTD, and PARNEL
June 9, 2014	F-1/A	- F-1/A As filed with the United States Securities and Exchange Commission on June 9, 2014 Registration No.
June 4, 2014	EX-3.1	PARNELL PHARMACEUTICALS HOLDINGS LTD ACN 137 904 413 TABLE OF CONTENTS Exhibit 3.1 PARNELL PHARMACEUTICALS HOLDINGS LTD ACN 137 904 413 CONSTITUTION TABLE OF CONTENTS 1. GENERAL 8 1.1. Name of Company 8 1.2. Liability of Shareholders 8 1.3. Replaceable rules 8 2. DEFINITIONS AND INTERPRETATION 8 2.1. Definitions 8 2.2. Interpretations 10 3. SHARES 10 3.1. Alteration of Capital 10 3.2. Increase of capital 11 3.3. Reduction of capital 12 3.4. Issue of shares and option
June 4, 2014	F-1/A	- F-1/A As filed with the United States Securities and Exchange Commission on June 4, 2014 Registration No.
June 4, 2014	EX-10.15	PARNELL PHARMACEUTICALS HOLDINGS LTD 2014 OMNIBUS EQUITY INCENTIVE PLAN Table of Contents Exhibit 10.15 PARNELL PHARMACEUTICALS HOLDINGS LTD 2014 OMNIBUS EQUITY INCENTIVE PLAN Table of Contents Page 1. History; Effective Date 1 2. Purposes of the Plan 1 3. Terminology 1 4. Administration 1 (a) Administration of the Plan 1 (b) Powers of the Administrator 1 (c) Delegation of Administrative Authority 3 (d) Non-Uniform Determinations 3 (e) Limited Liability; Advisors 3 (f) Indemnification
June 4, 2014	EX-10.17	Certain Defined Terms Used in Lock-up Agreement EX-10.17 6 v380313ex10-17.htm EXHIBIT 10.17 Exhibit 10.17 [Date] Jefferies LLC Piper Jaffray & Co As Representatives of the Several Underwriters c/o Jefferies LLC 520 Madison Avenue New York, New York 10022 c/o Piper Jaffray & Co 345 Park Avenue, 12th Floor New York, New York 10154 RE: Parnell Pharmaceuticals Holdings Ltd (including any successor entity, the “Company”) Ladies & Gentlemen: The unde
June 4, 2014	EX-10.16	DEED POLL given by 2013 Bondholders in favour of Parnell Pharmaceuticals Holdings Pty Ltd (ACN 137 904 413) Level 10 Atanaskovic Hartnell House 75-85 Elizabeth Street Sydney NSW Australia 2000 Exhibit 10.16 DEED POLL given by 2013 Bondholders in favour of Parnell Pharmaceuticals Holdings Pty Ltd (ACN 137 904 413) Level 10 Atanaskovic Hartnell House 75-85 Elizabeth Street Sydney NSW Australia 2000 “Liability limited by a scheme approved under Professional Standards Legislation” DEED POLL given on 30 May, 2014 by: The 2013 bondholders as listed in the Schedule (the “Bondholders”) in favou
June 4, 2014	CORRESP	- Unit 4, Century Estate 476 Gardeners Road Alexandria 2015 NSW Australia June 4, 2014 Via UPS and Email U.
May 19, 2014	EX-10.13	Each entity described in Schedule 1 Partners for Growth III, L.P. Revenue Sharing Deed Exhibit 10.13 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION Each entity described in Schedule 1 and Partners for Growth III, L.P. Revenue Sharing Deed CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PO
May 19, 2014	EX-10.8	PARNELL, INC. UCM/SREP-CORPORATE WOODS, LLC 40 CORPORATE WOODS SUITE 1170 9401 Indian Creek Parkway OVERLAND PARK, KANSAS 66210 STANDARD OFFICE LEASE Exhibit 10.8 LEASE PARNELL, INC. AND UCM/SREP-CORPORATE WOODS, LLC 40 CORPORATE WOODS SUITE 1170 9401 Indian Creek Parkway OVERLAND PARK, KANSAS 66210 STANDARD OFFICE LEASE 1. Basic Lease Provisions (“Basic Lease Provisions”). 1.1 Parties. This Standard Office Lease (“Lease”), dated for reference purposes only, March 6, 2013, is between UCM/SREP-CORPORATE WOODS, LLC, a Delaware limited liability c
May 19, 2014	EX-10.4	New South Wales Real Property Act 1900 EX-10.4 2 v378626ex10-4.htm EXHIBIT 10.4 Form: 07L License: 04-11-037 Licensee: Kemp Strang Leave this space clear. Affix additional pages to the top left-hand corner LEASE New South Wales Real Property Act 1900 PRIVACY NOTE: Section 31B of the Real Property Act 1900 (RP Act) authorises the Registrar General to collect the information required by this form for the establishment and maintenance of
May 19, 2014	F-1	- FORM F-1 As filed with the United States Securities and Exchange Commission on May 16, 2014 Registration No.
May 19, 2014	EX-10.5	SUPPLY AGREEMENT ON GONADORELIN ACETATE Exhibit 10.5 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION SUPPLY AGREEMENT ON GONADORELIN ACETATE This Agreement is made as of September 26, 2011 (the “Effective Date”) between Bachem AG, an entity organized
May 19, 2014	EX-10.14	ISSUED BY PARNELL PHARMACEUTICALS HOLDINGS PTY LIMITED Level 10 Atanaskovic Hartnell House 75-85 Elizabeth Street Sydney NSW Australia 2000 EX-10.14 6 v378626ex10-14.htm EXHIBIT 10.14 Exhibit 10.14 CONDITIONS OF 2013 BONDS ISSUED BY PARNELL PHARMACEUTICALS HOLDINGS PTY LIMITED Level 10 Atanaskovic Hartnell House 75-85 Elizabeth Street Sydney NSW Australia 2000 2013 Parnell Bonds Conditions - Final - 1 - 1. DEFINITIONS 1.1 Conditions In these Conditions, unless the context otherwise requires: “2013 Bond” means a bond with a Face Value
May 16, 2014	CORRESP	- Parnell Pharmaceuticals Holdings Pty Ltd Unit 4, Century Estate 476 Gardeners Road Alexandria 2015 NSW Australia May 16, 2014 Via UPS and Email U.
May 1, 2014	EX-10.12	Table of Contents Exhibit 10.12 LICENCE AGREEMENT CIMTECH PTY LIMITED and PARNELL TECHNOLOGIES PTY LTD Table of Contents Page 1. PRELIMINARY 1 1.1 Definitions 1 1.2 Interpretation 7 1.3 Currency 7 2. ROYALTY TERM 8 3. LICENCE OF LICENSED INTELLECTUAL PROPERTY 8 3.1 Grant of license to PARNELL 8 3.2 Technology transfer 9 3.3 Separate agreements 9 4. SUB-LICENSING 9 4.1 Grant of SUB-LICENSES 10 4.2 Provision of a cop
May 1, 2014	EX-10.1	DISTRIBUTION AND SUPPLY AGREEMENT PARNELL NORTH AMERICA PTY LTD ABN 36 138 251 537 VÉTOQUINOL CANADA INC Table of Contents Exhibit 10.1 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION DISTRIBUTION AND SUPPLY AGREEMENT PARNELL NORTH AMERICA PTY LTD ABN 36 138 251 537 and VÉTOQUINOL CANADA INC Table of Contents Page 1. Interpretation
May 1, 2014	EX-10.9	Supply Agreement for Pentosan Polysufate Active Pharmaceutical Ingredient Parnell Manufacturing Pty Ltd (ABN 46 138 251 582) IDT Australia Limited (ABN 66 066 522 970) Effective Date: 3 December 2013 TABLE OF CONTENTS Exhibit 10.9 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION Supply Agreement for Pentosan Polysufate Active Pharmaceutical Ingredient Between Parnell Manufacturing Pty Ltd (ABN 46 138 251 582) and IDT Australia
May 1, 2014	EX-10.6	SCHEDULE 1 COMPANIES TO WHICH ROBERT JOSEPH WILL BE APPOINTED DIRECTOR AND CHIEF EXECUTIVE OFFICER Exhibit 10.6 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION Unit 4, Century Estate 476 Gardeners Road Alexandria NSW 2015 PO Box 1035 Mascot NSW 1460 Telephone: 61-2-9667 4411 Facsimile: 61-2-9667 4139 Website:
May 1, 2014	EX-10.11	SUPPLY AGREEMENT EX-10.11 9 filename9.htm Exhibit 10.11 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION SUPPLY AGREEMENT This Supply Agreement (this “Agreement”) entered into on the 1st day of January 2014, is made by and betwee
May 1, 2014	EX-10.3	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK *, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION EX-10.3 4 filename4.htm Exhibit 10.3 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK *, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION Distribution and Supply Agreement Amendment 1 Parnell Europe Pty Limited AND Eli Lilly and Company This is Amendment number 1
May 1, 2014	DRSLTR	- Parnell Pharmaceuticals Holdings Pty Ltd Unit 4, Century Estate 476 Gardeners Road Alexandria 2015 NSW Australia May 1, 2014 Via UPS Securities and Exchange Commission Division of Corporation Finance 450 Fifth Street, N.
May 1, 2014	EX-10.10	CREDIT AGREEMENT dated as of January 23, 2014 PARNELL PHARMACEUTICALS HOLDINGS PTY LTD, and PARNELL, INC. as Borrowers, THE SUBSIDIARIES OF THE BORROWERS, as Guarantors, THE LENDERS PARTY HERETO, as Lenders, SWK FUNDING LLC, as Agent, Sole Lead Arran Exhibit 10.10 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION CREDIT AGREEMENT dated as of January 23, 2014 among PARNELL PHARMACEUTICALS HOLDINGS PTY LTD, and PARNELL, INC. as Borrowers, THE SUBSIDIARIES OF THE
May 1, 2014	DRS/A	- As filed with the United States Securities and Exchange Commission on May 1, 2014 Registration No.
May 1, 2014	EX-10.7	SCHEDULE 1 COMPANIES TO WHICH ROBERT JOSEPH WILL BE APPOINTED DIRECTOR AND CHIEF FINANCIAL OFFICER Exhibit 10.7 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION Unit 4, Century Estate 476 Gardeners Road Alexandria NSW 2015 PO Box 1035 Mascot NSW 1460 Telephone: 61-2-9667 4411 Facsimile: 61-2-9667 4139 Website:
May 1, 2014	EX-10.2	DISTRIBUTION AND SUPPLY AGREEMENT PARNELL EUROPE PTY LTD ABN A2 138 251 56A and ELANCO, a division of ELI LILLY and COMPANY Table of Contents EX-10.2 3 filename3.htm Exhibit 10.2 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION DISTRIBUTION AND SUPPLY AGREEMENT PARNELL EUROPE PTY LTD ABN A2 138 251 56A and ELANCO, a division of ELI LILLY and COMPANY Ta
March 26, 2014	EX-21.1	Parnell Pharmaceuticals Holdings Ltd Subsidiaries EXHIBIT 21.1 Parnell Pharmaceuticals Holdings Ltd Subsidiaries Subsidiary Name State or Other Jurisdiction of Incorporation Parnell Laboratories (Aust) Pty Ltd Australia Parnell Group Pty Ltd Australia Australian Pharma Services Pty Ltd Australia Parnell North America Pty Ltd Australia Parnell Europe Pty Ltd Australia Parnell Manufacturing Pty Ltd Australia Parnell Corporate Services Pty Ltd Austr
March 26, 2014	DRS	- As filed with the United States Securities and Exchange Commission on March 26, 2014 Registration No.

PARN / Parnell Pharmaceuticals Holdings Ltd. - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

Mga Batayang Estadistika

SEC Filings

SEC Filings (Chronological Order)